Acute Myeloid Leukemia (AML): It is estimated that 21,380 new cases of AML will be diagnosed, mostly in adults, in the United States in 2017.1
Indoximod may offer possibilities in acute myeloid leukemia2
NewLink Genetics’ indoximod is a small-molecule indoleamine 2,3-dioxygenase (IDO) pathway inhibitor that has the potential to disrupt mechanisms by which tumors evade the immune system.3,4
1. What Are the Key Statistics About Acute Myeloid Leukemia? https://clinicaltrials.gov/ct2/show/NCT02835729?term=indoximod&cond=Acute+Myeloid+Leukemia&rank=1. Accessed September 25, 2017 2. A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. https://clinicaltrials.gov/ct2/show/record/NCT02835729?term=indoximod&cond=AML&rank=1. Accessed September 25, 2017. 3. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34(3):137-143. 4. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like helper T cells. J Immunol. 2009;183(4):2475-2483.